U.S. Markets open in 7 hrs 25 mins
  • S&P Futures

    3,262.25
    -12.75 (-0.39%)
     
  • Dow Futures

    26,950.00
    -105.00 (-0.39%)
     
  • Nasdaq Futures

    10,927.25
    -61.75 (-0.56%)
     
  • Russell 2000 Futures

    1,476.30
    -6.50 (-0.44%)
     
  • Crude Oil

    39.22
    -0.09 (-0.23%)
     
  • Gold

    1,915.80
    +5.20 (+0.27%)
     
  • Silver

    24.60
    +0.21 (+0.87%)
     
  • EUR/USD

    1.1761
    -0.0012 (-0.1058%)
     
  • 10-Yr Bond

    0.6710
    0.0000 (0.00%)
     
  • Vix

    27.78
    +1.95 (+7.55%)
     
  • GBP/USD

    1.2804
    -0.0014 (-0.1076%)
     
  • BTC-USD

    10,485.42
    +47.69 (+0.46%)
     
  • CMC Crypto 200

    222.88
    -12.71 (-5.39%)
     
  • FTSE 100

    5,804.29
    -202.76 (-3.38%)
     
  • Nikkei 225

    23,360.30
    +40.90 (+0.18%)
     

Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference

Guardant Health, Inc.

REDWOOD CITY, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.

Guardant Health’s management is scheduled for a fireside chat on Tuesday, September 15 at 8:45 a.m. Pacific Time / 11:45 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.

About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360® and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Anna Czene
press@guardanthealth.com

Courtney Carroll
courtney.carroll@uncappedcommunications.com